Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Autor:	Bon-Kwan Goo, Yong-Rim Kwon, Seung-Hyun Jung, Yunsuk Choi, Je-Hwan Lee, Eun-Hye Hur, Sug Hyung Lee, Yeun-Jun Chung, Yoo-Jin Kim, Hye-Jung Kim, Seon-Hee Yim
Rok vydání:	2016
Předmět:	Adult Male 0301 basic medicine Oncology Gerontology medicine.medical_specialty Multivariate analysis Somatic cell Azacitidine Subgroup analysis medicine.disease_cause DNA Methyltransferase 3A Dioxygenases hypomethylating therapy 03 medical and health sciences 0302 clinical medicine Proto-Oncogene Proteins Internal medicine Hypomethylating Therapy Humans Medicine In patient DNA (Cytosine-5-)-Methyltransferases targeted sequencing Aged Mutation business.industry Myelodysplastic syndromes DNA Methylation Middle Aged Genes p53 Prognosis Splicing Factor U2AF medicine.disease myelodysplastic syndrome DNA-Binding Proteins Genes ras 030104 developmental biology Myelodysplastic Syndromes 030220 oncology & carcinogenesis Female business Research Paper medicine.drug
Zdroj:	Oncotarget
ISSN:	1949-2553
DOI:	10.18632/oncotarget.10526
Popis:	Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting response to HMT remains an unresolved issue. We aimed to identify mutations associated with response to HMT and survival in MDS. A total of 107 Korean patients with MDS who underwent HMT (57 responders and 50 non-responders) were enrolled. Targeted deep sequencing (median depth of coverage 1,623X) was performed for 26 candidate MDS genes. In multivariate analysis, no mutation was significantly associated with response to HMT, but a lower hemoglobin level (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39897507055f9fc34a29f99d1e440ba https://doi.org/10.18632/oncotarget.10526 Zobrazit plný text záznamu